Enhancing Source Credibility in Tobacco Regulatory Communications
2020. november 20. frissítette: Adam Goldstein, MD, MPH, UNC Lineberger Comprehensive Cancer Center
This study will assess the impact of cigarette constituent messages with and without FDA source and quit information in a randomized controlled trial.
The investigators hypothesize that cigarette constituent messages will increase intention to quit compared to messages about littering cigarettes (the control).
The investigators also hypothesize that constituent messages that include FDA source and quit information will increase intention to quit compared to messages without that information.
A tanulmány áttekintése
Állapot
Befejezve
Körülmények
Részletes leírás
The Family Smoking Prevention and Tobacco Control Act delegates the U.S. Food and Drug Administration (FDA) to communicate the risks of smoking to the public, among other tobacco regulatory responsibilities. Little research exists about how FDA, as a regulatory agency, should develop and deliver these messages, and whether they should include their source information on the ads. This study will assess the impact of cigarette constituent messages with and without FDA source and quit information in a randomized controlled trial.
Recruitment: People interested in participating will complete an online screener. Study staff will invite people eligible based on the screener to enroll in the study.
Informed Consent: The consent form will be shared with people who are eligible based on the screener in the invitation email. At the beginning of the baseline survey, participants will again review the consent form and will be asked to provide consent in order to enroll in the study.
Randomization: At the end of the baseline survey, survey software will randomly assign participants to one of the three study arms. Participants will have an equal chance of being randomized to each study arm.
Assessment: Participants will complete 18 computer based surveys during the study. The first baseline survey will take around 20 minutes to complete on day 0. Participants will then receive a survey each morning for days 1-15 that will include behavior measures as well as their assigned study intervention. These surveys will take approximately 5 minutes to complete. Participants will then complete a 20-minute survey on day 16, and day 32.
Detailed description of the intervention: Participants will receive an email with a link to a survey each morning for 15 days. During that survey they will be shown one message from their condition. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators designed the messages.
Tanulmány típusa
Beavatkozó
Beiratkozás (Tényleges)
845
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.
Tanulmányi helyek
-
-
North Carolina
-
Chapel Hill, North Carolina, Egyesült Államok, 27599
- University of North Carolina at Chapel Hill
-
-
Részvételi kritériumok
A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.
Jogosultsági kritériumok
Tanulmányozható életkorok
18 év (Felnőtt, Idősebb felnőtt)
Egészséges önkénteseket fogad
Nem
Tanulmányozható nemek
Összes
Leírás
Inclusion Criteria:
- Have smoked at least 100 cigarettes in his or her lifetime
- Currently smoke cigarettes every day or some days
- Work or home access to the internet
- Email account that is regularly used
- Lives in the US
- Comfortable taking a survey in English
- Able to complete a survey on a computer
- Able to complete surveys delivered via email
- Able to complete 3, 20 minute surveys during the study
- Able to complete surveys in the morning for 15 days
Exclusion Criteria:
- Currently using pharmacotherapy, a quitline, or a quit smoking program or support group for smoking cessation
- Participated in a research study about smoking cigarettes or using other tobacco products in the last 3 months
Tanulási terv
Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Megelőzés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Constituent message with FDA and quitline
Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect.
This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline.
Each condition has 5 messages that will be repeated 3 times in a counterbalanced order.
Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication.
Design of these messages was developed by our team.
|
Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect.
This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline.
Each condition has 5 messages that will be repeated 3 times in a counterbalanced order.
Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication.
Design of these messages was developed by our team.
|
|
Kísérleti: Constituent message without FDA and quitline
Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect.
This arm is identical to the arm above, except that it does not include FDA source or quit information.
Each condition has 5 messages that will be repeated 3 times in a counterbalanced order.
Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication.
Design of these messages was developed by our team.
|
Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect.
This arm is identical to the arm above, except that it does not include FDA source or quit information.
Each condition has 5 messages that will be repeated 3 times in a counterbalanced order.
Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication.
Design of these messages was developed by our team.
|
|
Egyéb: Littering message (Control)
Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message.
Each condition has 5 messages that will be repeated 3 times in a counterbalanced order.
Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication.
Design of these messages was developed by our team.
|
Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message.
Each condition has 5 messages that will be repeated 3 times in a counterbalanced order.
Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication.
Design of these messages was developed by our team.
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Quit Intentions
Időkeret: day 16
|
Average quit intention score measured at 16 days by survey.
Quit intention measured with 3 questions, the final quit intention score is a mean of the response to the 3 questions, on a scale of 1 to 4, where 1 indicates low intention to quit, and 4 indicates a high intention to quit.
|
day 16
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Number of Cigarettes Smoked Each Day
Időkeret: days 1-15
|
Measured daily by survey
|
days 1-15
|
|
Number of Cigarettes Forgone Each Day
Időkeret: days 1-15
|
Measured daily by survey
|
days 1-15
|
|
Number of Cigarettes Butted Out Each Day
Időkeret: days 1-15
|
Measured daily by survey
|
days 1-15
|
|
Quit Attempts During the Study
Időkeret: days 16 and 32
|
Measured by survey
|
days 16 and 32
|
|
Awareness of Quitline
Időkeret: day 16
|
Measured by survey
|
day 16
|
|
Recall of Quitline Phone Number
Időkeret: day 16
|
Measured by survey
|
day 16
|
|
Use of Quitline During the Study
Időkeret: days 16 and 32
|
Measured by survey
|
days 16 and 32
|
|
Intention to Use the Quitline
Időkeret: days 16 and 32
|
Measured by survey.
Intention to use the quitline was measured with one item on a 1 to 4 scale, where 1 indicates a low likelihood of calling the quitline, and 4 indicates a high likelihood of calling the quitline.
|
days 16 and 32
|
|
Quit Intentions
Időkeret: day 32
|
Average quit intention score measured at 32 days by survey.
Quit intention measured with 3 questions, the final quit intention score is a mean of the response to the 3 questions, on a scale of 1 to 4, where 1 indicates low intention to quit, and 4 indicates a high intention to quit.
|
day 32
|
|
Self Efficacy
Időkeret: days 16 and 32
|
Measured by survey.
Self efficacy measured with 1 question, on a scale of 1 to 5, where 1 indicates low self efficacy to quit, and 5 indicates a high self efficacy to quit smoking cigarettes.
|
days 16 and 32
|
|
Response Efficacy
Időkeret: days 16 and 32
|
Measured by survey.
Response efficacy measured with 1 question, on a scale of 1 to 5, where 1 indicates low response efficacy of quitting, and 5 indicates a high response efficacy of quitting smoking cigarettes.
|
days 16 and 32
|
Együttműködők és nyomozók
Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.
Együttműködők
Publikációk és hasznos linkek
A vizsgálattal kapcsolatos információk beviteléért felelős személy önkéntesen bocsátja rendelkezésre ezeket a kiadványokat. Ezek bármiről szólhatnak, ami a tanulmányhoz kapcsolódik.
Tanulmányi rekorddátumok
Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
2017. október 10.
Elsődleges befejezés (Tényleges)
2018. május 6.
A tanulmány befejezése (Tényleges)
2018. május 23.
Tanulmányi regisztráció dátumai
Először benyújtva
2017. november 7.
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
2017. november 7.
Első közzététel (Tényleges)
2017. november 13.
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
2020. november 24.
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
2020. november 20.
Utolsó ellenőrzés
2020. november 1.
Több információ
A tanulmányhoz kapcsolódó kifejezések
Egyéb vizsgálati azonosító számok
- 17-0610
- P50CA180907 (Az Egyesült Államok NIH támogatása/szerződése)
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Nem
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Nem
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .